## Kreos Capital VII €1.2 billion

### Unique Private Debt Strategy Lending to Pan-European Growth Companies

Compelling risk-return profile driven by senior-secured amortising loans with enhanced returns

Market leader with consistent +25-year track record

KREOS CAPITAL

Prospective Fund VII

Kreos provides private debt solutions to sponsored pan-European high-growth companies throughout their life cycle

Generating consistent, high contractual returns through a diversified portfolio of senior-secured, amortising loans with yield-enhancement upside

## The leading European growth debt fund manager



### **Kreos Strategy Overview**

#### European Growth Debt Leader

Pan-European market leader	<ul> <li>+25-year history - longest track record in the market. Pioneered asset class outside of the US in 1998</li> <li>Invest across the widest span of countries, markets, sectors &amp; stages - consistently broadening use cases</li> <li>Able to sustain a market leading share - limited competition driven by strong barriers to entry</li> </ul>
Robust and scalable infrastructure	<ul> <li>Deep market penetration via relationship-driven origination</li> <li>Dynamic origination &amp; execution engine with proven rigorous deal selection criteria</li> <li>45-strong team, backed up by seasoned operations, finance and legal infrastructure</li> </ul>

#### Market Defining Strategy

Proven investment thesis	<ul> <li>Providing senior-secured debt financing to sponsored, pan-European, high-growth companies</li> <li>Invest across companies' growth life-cycles - matching needs of business owners &amp; management teams</li> <li>Consistent and total focus on high-growth companies in the Technology and Healthcare sectors</li> </ul>
Flexible and fast cash return	<ul> <li>Monthly cash distributions to LPs from year 1 - rapid predictable return of capital from portfolio</li> <li>Security &amp; loan amortisation protect the downside, while yield-enhancing features generate further upside</li> <li>Each fund (~100 to ~130 facilities) broadly diversified by industry, geography and size</li> </ul>
Compelling risk / return profile	<ul> <li>~20% gross underwriting IRR driven by cash yield and yield enhancements</li> <li>Stable pricing, even through low interest-rate environment - ensures contractual IRR thresholds met</li> <li>No leverage used at the Fund level</li> </ul>



### Deep & broad coverage within Kreos's target market



- Entry-level
- Mid-stage
- Late-stage
- Late-stage+ / Scaling
- Pre-IPO & Post-IPO

#### Broad Geographic Coverage

 Investments in 19 different jurisdictions to date, throughout Europe & Israel



#### Focus on High-Growth Sectors


- Sectors & industries include:
  - Technology
  - Tech-Enabled Services
  - Software
  - Healthcare & Life Sciences

#### Range of Transaction Sizes

- Facilities up to €100m
- Scale with strongest performing companies



### Kreos has evolved with the market to cover all stages of a growth company's life-cycle



\*KVI includes a €152m top-up vehicle, with final closing in H1 2021, that co-invests alongside Kreos VI in transactions greater than or equal to €15 million

# Growth Debt specialists with unique market positioning

#### What do we invest in?

- High-growth companies with crossborder dynamics
- Strong management teams backed by trusted sponsors
- Companies close to profitability or with visible cash horizons
- Scalability, global expansion potential


#### Where do we invest?

#### • Throughout Europe & Israel

- Highly innovative sectors and business models (Tech & Healthcare)
- Markets under-served by established participants
- Alongside the increasingly strong growth equity sponsor market

#### How do we invest?

- Senior-secured facilities up to €100m with Kreos VII
- Customised terms based on monthly amortising facilities
- Typically, the only non-bank debt provider
- Strong lender alignment through exit driven yield enhancement features and relationships



### **Expanding team to meet growing market demand**

#### Uniquely experienced investing partner team











Aris Constantinides Maurizio PetitBon Sean Dunne Mårten Vading





+1/2

Parag Gandesha COO

#### **Growing Dedicated Investment Team**



Sonia Benhamida

Principal



Chris Church Principal

**Tim Fenwick** Alex Duffy Principal Vice President



David Fitzpatrick Ragna Portelli Vice President Vice President

Xixi Richter Vice President



Babulevich

Analyst



Uri Galai

Todd Spiers Vice President



Capodimonti

Analyst





+2/3

Guy Arbib Associate



**Investor Relations** 

Mat Pearse

Relations

Head of Investor

Maria Garcia

Associate

Yusuf Shah

Associate



Senior Analyst

Kailey Aliyar



Guillaume Senior Analyst

Keerthana Simon Visser Devarajan Senior Analyst Senior Analyst





Portfolio Analyst

Kristian Jones Martin Schutz Izabela Lisiecka Tommy McGilley Elena Melega Portfolio Director Financial Controller Accountant



Zarmila Thanachayan PQ Accountant





Fund Accountant Accountant



Varun Suchanti Data Analyst







Analyst





Lauren Walker New Hires

**Operations** 



Analvst





Jess Pallot-Cook HR Coordinator

Estelle Udensi Compliance



Holly Emerton Office Administrator Office Administrator Kreos



APITAL

8






















### **Enhancement of Kreos's Market-Leading Platform**



#### **Evolution of Kreos Team Since Inception**


- Scale & Expansion Kreos has one of the largest dedicated teams in the market with plans to expand to ~50 people during Kreos VII
- Portfolio Company Coverage multiple Kreos touchpoints for each portfolio company ensuring dynamic management & monitoring – more than sufficient coverage for Kreos VII deal flow
- Platform Growth through transaction experience from 750+ deals, Kreos has evolved a unique and highly-efficient investment platform & deal engine
- International Team Kreos team comprises many different nationalities with +15 languages spoken
- Depth of Experience the founders have worked together for +25 years and are supported by an experienced senior level team, associates & analysts
- Broad Geographical Coverage transaction experience in 19 different jurisdictions across the team



# Demand for Growth Capital Outweighs Supply

- Demand for Growth Debt has been steadily increasing as the European & Israeli growth eco-system has grown and matured and the use cases of this debt have evolved
- O Companies are continuing to stay private longer leading to an increase in larger, more later-stage deal flow
- Kreos invests across the growth life-cycle and can capitalize on the increasing demand at each stage

### Capital Demand / Supply Ratio for Growth Debt by Stage



### Accelerating market expansion in Kreos' eco-system

Kreos' growth debt solutions at each stage of a company's growth life cycle continues to provide a compelling risk-return profile for investors




Kreos is in a unique position as the leading growth debt platform to Tech & Healthcare companies in the European & Israeli growth eco-system

KREOS 3

## Growing eco-system moving larger & more-later stage

- Kreos' fund portfolios have evolved in line with the growth market companies are continuing to stay private longer leading to an increase in larger, more later-stage deal flow
- As a provider of finance across the entire growth life-cycle, Kreos is well-positioned to capitalize on this laterstage opportunity while retaining a foothold in the entry-stage market - facilitating origination and provide enhanced diversification to our limited partners
- Pricing & LTVs have remained consistent and within Kreos's target contractual yield of 12-14% and yield enhancement sophistication has increased, enhancing outcomes and contribution towards overall return



### **European Sponsor Transactions by Stage**

### **Kreos Portfolio Mix Over Time**


Late-Stage + /Scaling Late-Stage + 33% Mid 45% Mid 32% Entry Entry 22% 21% Kreos V Kreos VI\* KREOS 7

\*Includes Kreos VI Top-Fund

## Rate of Investment Increasing to Meet Market Demand

- Over the last five years, Kreos has increased annual commitment pace in response to broader market trends and increasing demand for our flexible finance solution
- Annual commitments have increased by +25% p.a. since 2017 while maintaining consistent, high pricing
- With the commencement of Kreos VII, 2022 was another strong year of deployment

### Kreos Capital - Annual Commitments (2017 - 2022)



Includes Kreos VI Top-Fund Data as of 31<sup>st</sup> December 2022

## ~20% gross underwriting IRR w/ downside protection

#### **Typical Aspects of Investment Structure Investment Return Profile Return Enhancing Features** ~20% Gross Underwriting Return Warrants, Yield enhancement securities ~6-8% Convertibles Exit fees Upside Equity co-Prepayments Contractual yield enhancement investments End-of-loan payments **Downside Protection Features Transaction** fees Advance payments/deposits Low LTV **Senior Security** (9-12%) 3-4 Year Term Amortisation 12-14% Monthly cash interest Contractual **Top-tier** Well capitalised by equity sponsors

**Return Drivers** 

### Kreos VII uniquely positioned to capitalize on market opportunity

€897m\* COMMITTED DEALS **Kreos VII** 

COMMENCED INVESTING - MAY 2022

9 FOLLOW-ONS €288m\*

€77m IC APPROVED TRANSACTIONS

# **€1.2bn**

FUNDRAISING TARGET

(FLEXIBILITY BEYOND TARGET TO ACCOMMODATE NEW LPS) €2.0bn+

TARGET PORTFOLIO COMMITMENTS (WITH ACTIVE RECYCLING) 32 NEW COMPANY INVESTMENTS €609m

~22% AVG. GROSS UNDERWRITING IRR 9-10% (In line with historical average) WEIGHTED AVERAGE LTV

### €800m+

RUN-RATE ANNUAL COMMITMENTS

 $22+_{months}$ AVG. UNDERWRITING CASH RUNWAY




Data as at Q1 2023 \*Excludes €20m of LP co-investment

# Kreos VII portfolio diversifying well in early ramp-up

#### Kreos portfolios are invested in a diverse range of deal stages & sizes with broad underlying industry exposures

- Reduced single asset exposure
- Wide geographical spread
- Broad deal size & stage range


#### Kreos VII Single Asset Exposure €897m Commitments / 41 Companies



- Average Position Exposure is currently ~1% of Target Portfolio Amount (€2.0bn+)
- Further diversification will occur as portfolio continues to ramp up

- No specific industries concentration
- Diversified sponsor coverage
- Global revenue generation

#### Kreos VII Portfolio Mix - Commitments to date




- Stage mix consistent with prior funds & emphasizes Kreos' shift to more mid & late-stage companies
- Later-stage commitments expected to grow driven by follow-on activity later in commitment period




## Kreos VII exposure to positive underlying trends

#### **Kreos VII Sector Diversification & KPIs**




#### Kreos VII Commitment & Geographical Diversification



### **Conservative approach in current market environment**

Kreos is utilising 25+ years of investment experience to conservatively deploy capital in the current market environment



- Increased focus on Enterprise / SaaS-based and recurring revenue business models
- Increasing covenant usage (e.g., minimum cash covenants / LTV covenants etc.)
- Avoiding high burn rates, inflexible cost base and low gross margin business models
- Increased use of floating rates and structuring of yield enhancement feature




# **Ramping portfolio of resilient & growing companies**

### Examples of new portfolio companies



### Examples of re-up portfolio companies




Data as at Q12023 \* Excludes €20m of LP co-investment

## Near-term pipeline strong with continued tailwinds

- Loss of key market participant SVB's collapse presents a unique opportunity for Kreos to capitalise as the only lender of scale in the market
- Flight to quality & scale Kreos' leadership position ensures it will remain as the go-to lender
- Significant pipeline of opportunities as companies stay private longer and some IPOs are postponed there is a growing opportunity for top-tier late-stage companies with attractive risk-reward profile
- Attractive entry valuations market price adjustments can mean attractive entry points for yield enhancement securities

### Kreos Deal pipeline – June 2023



## New opportunities have been created

- Kreos pipeline & deal flow has increased in light of market dynamics, including turmoil created by SVB's demise
- Market has experienced a scaling back of non-traditional or "tourist" investors
- Uncertainty among banking institutions has also driven investment opportunities more towards private capital where Kreos can benefit from a flight to scale and quality


### Key Origination Sources That Kreos Will Benefit From:



# Kreos positioned to capitalise on uncertainty & provide stability to the eco-system

A stable investor in a time of uncertainty	<ul> <li>Kreos are the largest growth debt fund in Europe &amp; Israel with more than €1.0bn of deployable capital available</li> <li>Since 1998, Kreos has pioneered the asset class outside of the US, investing more than €5.2bn across 750+ transactions</li> <li>We have the largest team, and more than 25 years of experience working with high-growth, innovative &amp; disruptive companies</li> <li>We have a reputation for flexibility, deliverability and reliability having never missed or reneged on a drawdown request in our history</li> </ul>
Dislocated sector underserved by traditional market participants	<ul> <li>The Growth Debt market continues to grow but remains underserved by traditional market participants (banks / other senior lenders)</li> <li>Having operated in the market for 25+ years, Kreos is uniquely placed to capitalize on the growing funding need for European &amp; Israeli businesses</li> </ul>
Loss of large competitor in the market	<ul> <li>Alongside SVB, Kreos Capital have been the most active participants in the European &amp; Israeli growth debt market</li> <li>With the collapse of SVB, there is a significant funding gap that has now opened in the market</li> <li>Kreos is well-positioned to capitalise as the only lender of scale</li> </ul>
Capacity within Kreos VII	<ul> <li>Kreos VII has raised ~€1.1bn towards it's €1.2bn target but has capacity to accommodate new investors up to the hard-cap of €1.5bn</li> <li>Additional capital allows Kreos to support the growth eco-system, consolidate our market leading position and provide additional diversification benefits to Kreos LPs</li> </ul>

# Kreos complements LP portfolios with a compelling risk-return profile



#### Private Market Gross IRR expectations with deviation

 Kreos has consistently generated gross, fund-level returns in excess of 18%

- Kreos returns are very predictable - 12-14% generated from contractual return
- Yield enhancement features provide opportunity for upside
- Senior-security, low LTV ratios, diversification and amortisation help to mitigate risk and reduce losses
- Monthly cash payments provide companies with flexibility compared to restrictive financial covenants

# Strong relationship-driven origination strategy across the full growth life-cycle

#### 'Network effect' benefits Kreos with enhanced deal flow and origination


Following 25+ years operating, and 750+ completed transactions in the European & Israeli Growth ecosystems, Kreos are uniquely positioned with equity sponsors and management teams as the lender of choice through every stage of a company's growth life cycle

#### Sponsors

A significant majority of Qualified Leads are originated from Kreos' unparalleled network of top-tier equity sponsors

This network extends across the whole growth life-cycle, from entry-level participants through to large growth and private equity sponsors

#### **Kreos Origination by Deal Source**




#### Follow-ons & Mgmt. Teams

>45% of Kreos deal origination is from follow-on investments and repeat management teams

Having backed >500 companies since 1998, Kreos are uniquely positioned to scale our facilities through every stage of a company's growth life cycle




# Kreos Platform Network Effect – Power of scale, global relationships & 25 years of leadership



## **Rigorous selection from robust deal pipeline**

Although demand for finance is high, Kreos has maintained disciplined underwriting, risk / reward pricing & consistent LTV ratios


#### KVII accumulated deal pipeline (Q1 2022 – Q1 2023)



# Kreos uses key criteria to select & underwrite opportunities

- Rigorous selection process from trusted sponsor deal flow
- Continuous networking with sponsors and management teams
- Focus on premium high-growth companies with a bias toward later-stage
- Follow-on facilities to existing portfolio companies that have proven themselves and built value

### **Kreos Typical Criteria for Preliminary Screening**



## Application of a proprietary deal rating model

#### **Debt Rating**

50% DEAL RATING WEIGHT

Measures the Value at Risk for a given Commitment and compares it with the Kreos base line requirement of the portfolio:

- Stress testing and sensitivity analysis of company financials
- o Liquidity risk points
- Expected amount to be drawn down pursuant to a commitment
- Value of all cash repayments until next risk point
- o Collateral value of Kreos security

#### **Sponsor Rating**

25% DEAL RATING WEIGHT

Measures the relative strength, dynamics and experience of the lead and sponsor syndicate:

- o Industry / Sponsor Track record
- History of flexibility and longterm support
- Previous deals completed with the sponsor & working experience
- o Dry powder available / reserved
- Stage in the life cycle of sponsor's fund
- o Lead Partner in charge

#### Yield Enhancement Rating




Measures the relative probability and significance of a yield enhancement return

- Amount, form & structure of yield enhancement
- Exercise price of equity
- Likely timing, amount and pricing of additional financing or exit
- Likelihood of a prepayment
- Comp analysis of previous M&A transactions and publicly listed companies

Each element of the deal rating model is assigned a value of 1 - 5

KREOS CAPITAL 28

### Well-tested and disciplined deal-execution process






# Kreos Market Leadership: Competitive advantages & barriers to entry


	<ul> <li>Fund Size &amp; Resources – Kreos is the largest independent debt provider operating in the growth market</li> <li>Deal Scale – Kreos can scale up with its portfolio companies, financing every stage of the growth life-cycle</li> <li>Longevity &amp; experience – only team in the pan-European market that has been through multiple cycles</li> </ul>
Competitive advantages	<ul> <li>Unique approaches after +750 transactions – focus on optimal risk/reward profiles to enhance returns</li> <li>Preferred deal flow &amp; access – strong long-term relationships w/ top-tier sponsors in the market</li> <li>Deal engine – power of iteration, operational infrastructure and significant team are hard to replicate</li> <li>Geography – partners on the ground and experience of cross border transactions in 19 jurisdictions</li> <li>Industry coverage – broad experience, highly diversified portfolio and specialist knowledge in healthcare</li> <li>Flexibility – to customise transactions and significantly boost returns</li> <li>Workout – track record of successful active management in distress to turn losers into winners</li> <li>Structure – minimal regulatory or internal bureaucratic requirements allow flexibility &amp; speed</li> <li>Independence – not dependent on credit lines or leverage to meet lending commitments or LP returns</li> </ul>
Barriers to entry	<ul> <li>Sponsor relationships – long-term partnerships with top-tier sponsors are vital – as Kreos has built over multiple business cycles across all regions, both for deal flow as well as monitoring</li> <li>Management relationships – relationships with managers take years to build &amp; create proprietary deal flow</li> <li>Geography – multiple legal systems, insolvency practice, business cultures, sponsors &amp; company networks</li> <li>Trust &amp; dependability – management and sponsors driven by trust in a known partner and not only price</li> </ul>

KREOS CAPITAL 30

# Kreos IV–VII: ~€3.4bn committed with consistent strong performance



# Granular portfolio generates predictable LP cash flows




- 30-40% of called capital repaid to LPs within 4 years
- o c.100% of called capital repaid to LPs by end of year 6

\*Kreos V commitment period ended after 3 years due to Kreos VI initial deployment.. Kreos VI commitment period is expected to be between 3-4 years in duration depending on first draw down from Kreos VII \*\*Kreos V and Kreos VI DPI has been projected out using current debt cash flow projections




### Low net loss rate, strong security, high recovery



- Monthly amortising facilities reduce risk and increase recoveries
  - Senior secured loans typically across the whole business and core assets
  - Control and significant experience in the event of distress or workout
  - Strong track record of enhancing returns in rescheduling scenarios

KREOS CAPITAL 33



\*Excluding two transactions in Kreos I that do not meet Kreos credit rating and commitment criteria post-2001 \*\* Cliffwater Direct Lending Index of Venture Loans – dataset runs from 31 March 2005 – 31 March 2022 \*\*\* Cliffwater Direct Lending Index of Senior Loans – dataset runs from 30 September 2010 – 31 March 2022

# Investing in a future driven by increased digitisation and healthcare focus



### A continuing growth story over 25+ years with key learnings from different market cycles & disruptions

2000-2001 Dotcom crash	2008-2009 Credit Crunch / GFC	2020 and beyond COVID, SVB and
• Established ourselves as <i>integral part</i> of growth ecosystem, pioneered the growth debt market in Europe, educated market and built strong and	<ul> <li>Focused on growth businesses at <i>cusp</i> of profitability</li> <li>Learnt to work-out distressed</li> </ul>	<ul> <li>Largest &amp; longest operating non- bank lender in the eco-system</li> <li>Oriented portfolio towards even later-</li> </ul>
<i>trusted relationships</i> with sponsors and companies	situations by <i>selling companies on</i> <i>"going concern" basis</i> and leveraging off sponsors capital	<i>stage companies</i> with average revenue over €65 million
<ul> <li>Following dotcom crash built proprietary <i>3-focus rating model</i></li> </ul>	<ul> <li>High <i>portfolio diversification</i> as risk- management tool</li> </ul>	<ul> <li>Scaled funds to meet market demands and finance the <i>full growth life-cycle</i> <i>journey</i></li> </ul>
<ul> <li>Learnt to avoid bridge financing situations and assure <i>long cash</i> <i>runways</i> when underwriting transactions</li> </ul>	<ul> <li>Maintained <i>low LTV ratios</i> of c.10% providing incentives for sponsors to continue adding capital</li> </ul>	<ul> <li>Introduced cash-based heatmap portfolio management tools to monitor risk in real-time and steer</li> </ul>
<ul> <li>Removed all financial leverage at fund level allowing us maximum operational flexibility</li> </ul>	• Began <i>positively repricing deals</i> in restructuring situations creating higher returns out of challenging situations	sponsors and companies towards right decisions

Positioned ourselves to *capture opportunities* that market disruptions
 may cause

#### Through multiple market cycles Kreos has grown and evolved

features to capture upside

Introduced more sophistication in

structuring yield enhancement

35

### **Summary Overview**

Compelling risk-return profile, high returns, low underlying risk	<ul> <li>Senior risk with junior returns: specialised approach to target markets</li> <li>~20% gross underwriting IRR driven by cash yield and yield enhancements</li> <li>Low net losses from senior security, amortisation, high diversification and low LTV</li> </ul>
Flexible and fast capital returns, predictable, yet with upside	<ul> <li>Monthly cash distributions to LPs from year 1</li> <li>Underpinned by rapid predictable return of capital from portfolio</li> <li>Yield-enhancing features generate further distributions and returns</li> </ul>
Pan-European market leader with unique +25-year track record	<ul> <li>+25 years core senior team team - +€5.2bn committed in 750+ transactions</li> <li>Widest span of markets, sectors, stages - broadening use cases, strong barriers to entry</li> <li>Proven rigorous deal selection criteria, dynamic origination &amp; execution engine with active deal management, robust and tested operations and legal infrastructure</li> </ul>
Very strong sponsor network drives robust deal pipeline	<ul> <li>Deep market penetration via relationship-driven deal flow, consistent pricing – over 7 funds</li> <li>Long-term relationships established over +25 years through three market cycles</li> <li>Consistent strong deal flow diversified across multiple metrics</li> </ul>
Favourable market evolution and competitive landscape	<ul> <li>Kreos's experience and fund size can address larger, more later-stage opportunities</li> <li>European markets have demonstrated high barriers to entry</li> <li>Competition is fragmented and can typically not address all segments and stages</li> </ul>
Benefits to LPs	<ul> <li>Complementary to core private debt and private equity portfolio</li> <li>Compelling risk-return profile driven by the senior security &amp; amortisation, contracted debt yield &amp; yield enhancers, and the underlying growth &amp; value-creation of the portfolio</li> <li>The strategy has been proven over +25 years and three business cycles</li> </ul>



### Notice

PROPRIETARY AND CONFIDENTIAL TO KREOS CAPITAL.

This document is being made available on a confidential basis and is being furnished by Kreos Capital solely for use by qualified prospective investors in preliminary discussions regarding a purchase of limited partnership interests (the "Interests") in Kreos Capital VII L.P. (the "Fund").

In considering any performance data contained herein, prospective investors should bear in mind that past or targeted performance is not indicative of future results, and there can be no assurance that the Fund will achieve comparable results or that target returns will be met. Prospective investors should also bear in mind that past or targeted portfolio characteristics are not indicative of future portfolio characteristics and there can be no assurance that the Fund will have comparable portfolio characteristics or that target portfolio characteristics will be achieved. Nothing contained herein should be deemed to be a prediction or projection of future performance of the Fund.

The presentation is confidential and may not be reproduced. The presentation was prepared without regard to the specific objectives, financial situation or needs of any particular person who may receive it. Under no circumstances is this presentation to be used or considered as an offer to sell or a solicitation of an offer to buy, any security. Any such offering may be made only by the definitive provisions provided for in the operating documents of the Fund, which will be made available to potential investors, and which should be read carefully by potential investors and their advisors. The discussion herein is qualified in its entirety by reference to the detailed information that appear in the operating documents of the Fund, and other definitive Fund documents. Such definitive Fund documents will govern in the event of a conflict between the information contained herein and therein. Except where otherwise indicated herein, the information provided herein is based on matters as they exist as of the date of preparation and not as of any future date and will not be updated or otherwise revised to reflect information that subsequently becomes available, or circumstances existing or changes occurring after the date hereof.

This presentation is not intended to be relied upon as the basis for an investment decision, and this presentation is not, and should not be assumed to be, complete. In making an investment decision, prospective investors should conduct their own investigation and analysis of the data and descriptions set forth in this presentation and must rely on their own examination of the investment opportunity, including the merits and risks involved. Prospective investors will be given the opportunity to review the actual documentation that will govern the rights and obligations of the parties. Qualified prospective purchasers may obtain from Kreos Capital such additional available information as they may reasonably request. Purchase of the Interests is suitable only as an investment for, and will be offered only to, persons who have, directly or through qualified representatives, the ability to evaluate the merits and risks of an investment in the Interests and the ability to assume the economic risks involved in such investment.

No person has been authorized to give any information or to make any representations other than to be contained in the definitive Fund documents. The contents of this presentation are not to be construed as legal, accounting, business or tax advice. Each prospective investor should consult its own attorney, accountant, business advisor and tax advisor as to legal, accounting, business and tax advice. Kreos Capital is not recommending that any recipient of this presentation invest in the Interests, and none of them represent or warrant that the Interests are a suitable investment for such recipient.

The information contained herein is proprietary and confidential and may contain commercial or financial information, trade secrets and/or intellectual property of the Fund and/or its affiliates. Although the information used in this presentation was taken from sources believed to be reliable, there is no representation, warranty or endorsement (expressed or implied) made as to the accuracy, reliability, adequacy or completeness of any information or analysis contained herein. Kreos Capital expressly disclaims any and all liability that may be based on such information, errors therein or omissions there from. The past performance of any investment funds, joint ventures or other investment products managed or controlled by Kreos Capital or any of its affiliates may not be indicative of the results that the Fund may be able to achieve. Furthermore, the nature of, and risks associated with, the Fund's investments may differ from those investments and strategies undertaken historically by affiliates of Kreos Capital with respect to other portfolios or investment vehicles they manage. There can be no assurance that the Fund's investments will perform as well as these past investments or that the Fund will be able to avoid losses.

Certain information in this presentation constitutes forward-looking statements. Due to various risks, uncertainties and assumptions made in our analysis, actual events or results or the actual performance of the types of investments covered by this presentation may differ materially from those described. The information herein reflects our current views only, are subject to change, and are not intended to be promissory or relied upon by prospective investors. There can be no certainty that events will turn out as we have opined herein. An investment in the Fund is speculative and involves a high degree of risk and is suitable only for sophisticated investors who can be ar substantial investment losses and have no need for liquidity. A prospective investor should consult with its advisors. No assurance or guarantees can be given that the Fund's investment strategy will prove successful and/or that the investment objectives of the Fund will be achieved or that an investor will receive a return of all or part of its investment (and investment results may vary substantially over any given time period).

The Interests described herein, when and if offered, will not be registered under the Securities Act of 1933, as amended (the "1933 Act") or any state or foreign securities laws, and the Interests will be offered and sold only to persons that are "accredited investors" (as defined in Regulation D under the 1933 Act) and "qualified purchasers" (as defined in the Investment Company Act of 1940, as amended (the "Investment Company Act")). The Interests will be subject to certain restrictions on transferability and resale contained in the Fund documents. The Interests have not been approved or disapproved by the Securities and Exchange Commission or any other state or foreign securities regulator. It is anticipated that the Fund will be exempt from the registration requirements of the Investment Company Act, and investors will not be entitled to the protections of such Act.

KREOS CAPITAL 37

### Contact

Matthew Pearse Investor Relations Kreos Capital Tel: +44-20-7758-3450 mat@kreoscapital.com / IR@kreoscapital.com www.kreoscapital.com

